StageLoan | Alive
Last Raised$1.5M | 3 yrs ago
About OptiScan Biomedical
OptiScan Biomedical has developed a monitoring platform for use in hospital intensive care units (ICU) to support clinicians in detecting changes more rapidly in critically ill patients, enabling more timely intervention. The OptiScanner platform is presently focused on delivering automated bedside glucose monitoring to support clinicians' reach and maintain the right level of glucose control.
Missing: OptiScan Biomedical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: OptiScan Biomedical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing OptiScan Biomedical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
OptiScan Biomedical is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
OptiScan Biomedical Patents
OptiScan Biomedical has filed 73 patents.
The 3 most popular patent topics include:
- Analytical chemistry
- Fluid dynamics
Computer memory, Analytical chemistry, Blood tests, Anticoagulants, Medical equipment
Computer memory, Analytical chemistry, Blood tests, Anticoagulants, Medical equipment
Latest OptiScan Biomedical News
Nov 16, 2020
Three New Members Elected to Titan Medical's Board Board now consists of a majority of independent corporate directors. Business Wire11.16.20 Titan Medical Inc. , a medical device company focused on the design and development of robotic surgical technologies for single access surgery, announced the election of Paul Cataford, Anthony J. Giovinazzo, and Cary G. Vance to its Board of Directors. All three individuals were nominated by the Board and were approved by shareholders voting at the company’s Annual and Special Meeting of Shareholders (AGM). Subsequent to the AGM, the board held a meeting and the following elections to board committees were made: Audit Committee: Chair, Paul Cataford; members – Anthony Giovinazzo, Cary Vance. All three members are independent and audit committee financial experts Compensation Committee: Chair, Cary Vance; members – Paul Cataford, Anthony Giovinazzo. Governance and Nominating Committee: Chair, Anthony Giovinazzo; members – Cary Vance, Paul Cataford. The new directors join President, CEO, and Board Chairman David McNally, and Director Stephen Randall, who recently retired from the company as chief financial officer after serving the company for more than 10 years. The board now consists of a majority of independent corporate directors. “We strategically sought this strong team, with its significant experience leading young companies with innovative technologies through highly regulated environments to commercialization,” said McNally. “We’ve had a very productive first meeting, designating committee chairmanships for governance, reporting and communication, and compensation. This active board is already undertaking the initiative to develop and execute a comprehensive investor communications strategy based on the best practices of similar development stage companies.” Cataford is the CEO and co-founder of Zephyr Sleep Technologies Inc., a medical device company specializing in the treatment and diagnoses of sleep-disordered breathing. He brings significant technology transfer and early stage company experience to Titan Medical’s board and has served as independent corporate director on a number of public boards of directors at companies listed on the TSX, Nasdaq and TSXV including: Sierra Wireless Inc., Trakopolis IoT Corp., SemiBioSys Genetics Inc., and AGJunction Inc. Cataford earned a bachelor of science degree in mechanical engineering from Queen’s University, an MBA specializing in finance from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors - Directors College, Rotman School of Business at the University of Toronto. Giovinazzo is a director and Governance/Nominating Committee chair on Titan Medical’s board of directors. As such, he will drive continuous improvement of the company’s governance practices, and has already overseen the appointment of qualified independent committee chairs and a lead independent director. Giovinazzo is a director and executive chairman on the board of Sublimity Therapeutics, a private late clinical stage biopharmaceutical company addressing gastrointestinal and autoimmune diseases. He is a co-inventor of the recent U.S. Food and Drug Administration-approved drug Kynmobi, developed by Cynapsus Therapeutics Inc., where Giovinazzo was also CEO and a director until Cynapsus was acquired in an all-cash transaction with Sunovion Pharmaceuticals Inc. for CAD $841 million. In 2017, Giovinazzo was chosen as the inaugural recipient of the Bloom Burton Award. Giovinazzo has a Chartered Director (C.Dir.) and Audit Committee Certification (ACC) from The Directors College and the DeGroote School of Business at McMaster University. He earned a bachelor of arts degree in economics and accounting from McMaster University and an MBA from IMD Geneva, Switzerland. Vance is a director and the company’s Compensation Committee chair and will lead and update the company’s compensation policies and philosophies. Vance serves on the AdvaMed Accel Board of Directors and is currently principal, Vance Consulting Group LLC., and was most recently president and CEO at OptiScan Biomedical Corporation. He previously served as president and CEO at Myoscience Incorporated, and president and CEO of Hansen Medical Inc. Prior to Hansen, Vance served in various global executive leadership roles at Teleflex, Covidien, and GE Healthcare. Vance is Lean/Six Sigma Black Belt certified, and earned a bachelor of arts degree in economics and an MBA from Marquette University.
OptiScan Biomedical Frequently Asked Questions (FAQ)
When was OptiScan Biomedical founded?
OptiScan Biomedical was founded in 1994.
Where is OptiScan Biomedical's headquarters?
OptiScan Biomedical's headquarters is located at 24590 Clawiter Road, Hayward.
What is OptiScan Biomedical's latest funding round?
OptiScan Biomedical's latest funding round is Loan.
How much did OptiScan Biomedical raise?
OptiScan Biomedical raised a total of $182.26M.
Who are the investors of OptiScan Biomedical?
Investors of OptiScan Biomedical include Paycheck Protection Program, MedVenture Associates, NGN Capital, Wexford Capital, Xeraya Capital and 13 more.
Who are OptiScan Biomedical's competitors?
Competitors of OptiScan Biomedical include Cardiopulmonary, GluMetrics, Sensible Medical Innovations, Chimerix, GlySure, Impulse Monitoring, Medingo, Kemeta, Navotek Medical, ArKal Medical and 12 more.
Compare OptiScan Biomedical to Competitors
Solianis is a Swiss medical device company developing products for physiological monitoring
Sensible Medical Innovation develops a sensing and monitoring technology that provides actionable and accurate data for guiding the management and treatment of several chronic medical conditions.
technology for real-time monitoring of the metabolic state of the patient and as a endpoint of resuscitationn nCritisense's first generation product - the "CritiView" is an patient monitoring system providing real-time continuous information via four physiological parameters, sensed at the tissue level, reflecting the systemic metabolic state. nCritiView is the only device providing continuous, real-time multi-parametric physiological data at the tissue and cellular level, by monitoring the mitochondrial function and the microcirculatory blood flow and oxygen saturation.n
Cellatope uses a platform, CB-CAPs (Cell-Bound Complement Activation Products), to develop an early identification and monitoring solution for autoimmune diseases
GlySure has developed a continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of Tight Glycemic Control and Intensive Insulin Therapy. The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of ICU stay.
IntelliDx, Inc. is a development stage medical device company focused on the commercialization of an automated blood glucose monitoring device.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.